Langerhans Cell Histiocytosis of the Uvea with a Ciliochoroidal Mass: A Case Report of Management with Systemic Therapy.

IF 0.7 Q4 OPHTHALMOLOGY

Case Reports in Ophthalmological Medicine Pub Date : 2023-01-01 DOI:10.1155/2023/5543131

Fariba Ghassemi, Hamid Riazi-Esfahani, Nazanin Ebrahimiadib, Abdulrahim Amini, Zahra Mahdizad

{"title":"Langerhans Cell Histiocytosis of the Uvea with a Ciliochoroidal Mass: A Case Report of Management with Systemic Therapy.","authors":"Fariba Ghassemi, Hamid Riazi-Esfahani, Nazanin Ebrahimiadib, Abdulrahim Amini, Zahra Mahdizad","doi":"10.1155/2023/5543131","DOIUrl":null,"url":null,"abstract":"Background: This study is aimed at exploring a case of choroidal Langerhans cell histiocytosis (LCH) successfully treated with systemic corticosteroid and immunosuppressant. Case presentation. A 24-year-old man with known multisystem LCH developed loss of vision, ocular pain, conjunctival injection, panuveitis, and a ciliochoroidal mass. After receiving an intravenous methylprednisolone pulse, oral high-dose corticosteroids, and methotrexate, the mass resolved quickly and completely without flare-ups during 6 months of follow-up.Conclusions: Intraocular involvement of LCH is rare and can present with or without a history of multisystemic disease. The diagnosis is challenging, and the standard treatment is not established. Systemic anti-inflammatory and immunosuppressive therapy could be an effective treatment, as the LCH itself contains an essential element of inflammation and the symptoms may be mainly inflammatory.","PeriodicalId":9603,"journal":{"name":"Case Reports in Ophthalmological Medicine","volume":"2023 ","pages":"5543131"},"PeriodicalIF":0.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491478/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Ophthalmological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/5543131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study is aimed at exploring a case of choroidal Langerhans cell histiocytosis (LCH) successfully treated with systemic corticosteroid and immunosuppressant. Case presentation. A 24-year-old man with known multisystem LCH developed loss of vision, ocular pain, conjunctival injection, panuveitis, and a ciliochoroidal mass. After receiving an intravenous methylprednisolone pulse, oral high-dose corticosteroids, and methotrexate, the mass resolved quickly and completely without flare-ups during 6 months of follow-up.

Conclusions: Intraocular involvement of LCH is rare and can present with or without a history of multisystemic disease. The diagnosis is challenging, and the standard treatment is not established. Systemic anti-inflammatory and immunosuppressive therapy could be an effective treatment, as the LCH itself contains an essential element of inflammation and the symptoms may be mainly inflammatory.

Abstract Image

查看原文本刊更多论文

伴有纤毛脉络膜肿块的葡萄膜朗格汉斯细胞组织细胞增多症:采用全身治疗的一例报告。

背景:本研究旨在探讨一例脉络膜朗格汉斯细胞组织细胞增多症(LCH)成功治疗全身皮质类固醇和免疫抑制剂。案例演示。一名24岁男性多系统LCH患者出现视力丧失、眼痛、结膜注射、全葡萄膜炎和纤毛脉络膜肿块。在接受静脉注射甲基强的松龙脉冲、口服大剂量皮质类固醇和甲氨蝶呤后，在6个月的随访中，肿块迅速消失，没有复发。结论:LCH的眼内受累是罕见的，可伴有或不伴有多系统疾病史。诊断具有挑战性，标准治疗方法尚未建立。全身抗炎和免疫抑制治疗可能是一种有效的治疗方法，因为LCH本身含有炎症的基本成分，症状可能以炎症为主。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Ophthalmological Medicine OPHTHALMOLOGY-

自引率

0.00%

发文量

审稿时长

14 weeks